ABBV vs RPRX Stock Comparison
Compare ABBV and RPRX across AIQ Score, fundamentals, valuation, momentum, risk, analyst expectations and current market evidence.
What is the main difference between ABBV and RPRX?
RPRX leads the current stock comparison as Royalty Pharma plc, with the clearest separation coming from value and the broader AIQ evidence mix.
AlgovestIQ AIQ Comparison
AbbVie Inc. vs Royalty Pharma plc
RPRX leads
RPRX leads by 7 AIQ points, primarily on Value and Momentum. Wall Street currently favors ABBV on target upside.
Competitive: 5 of 6 evidence groups support RPRX, and its current signal state is conflicted.
AbbVie Inc.
Royalty Pharma plc
The Algovestiq AIQ Score currently favors RPRX over ABBV, 59 versus 52 as of Sep 6, 2026. RPRX's advantage is driven primarily by stronger value and momentum, while ABBV holds the stronger quality profile. RPRX also shows the stronger technical structure relative to its 50-day moving average, though analyst target upside currently favors ABBV. 5 of 6 covered evidence groups favor RPRX today, and the comparison is rated Competitive on stability: the leader is throwing conflicting signals. RPRX lead: Stable — the AIQ differential has held near 7 points over 30 sessions.
Compare AbbVie Inc. and Royalty Pharma plc across the Algovestiq AIQ Score, valuation, quality, momentum, risk, technicals and analyst expectations.
Performance over time
Price-return comparison using available daily close history.
Total return comparison
Growth of $10,000
Based on available close-price history. Distribution reinvestment is not added unless already reflected in the source series.
Compare ABBV and RPRX against another ticker
Open a multi-ticker workspace without changing this focused pair page.
AIQ Factor Divergence
Where the two separate, on the four dimensions behind the AIQ Score. Bars read outward from a shared zero: further from the centre is a wider gap.
- Value30%36 vs 51RPRX +15
- Momentum25%65 vs 79RPRX +14
- Risk Resilience15%44 vs 53RPRX +9
- Quality30%60 vs 53ABBV +7
5 of 6 evidence groups favor RPRX. RPRX’s edge is concentrated in value and momentum; ABBV keeps a meaningful quality edge.
What changed since the last close
Latest scored session 2026-09-05, compared against the prior scored session 2026-09-04.
No factor moved materially.
No new signals fired.
No factor moved materially.
No new signals fired.
RPRX's lead was unchanged in the latest snapshot.
Deeper signal detail for each name lives on its own signals page — ABBV and RPRX both carry a full feed there.
The central trade-off
RPRX (Royalty Pharma plc): the stronger current systematic profile, led by value and momentum.
ABBV (AbbVie Inc.): the counter-case, on quality, analyst expectations.
The AIQ Score and Wall Street therefore point in different directions on this pair.
Which one fits your objective
The same two names rank differently depending on what you are optimizing for. All six reads are shown at once — none of them is hidden behind a toggle.
Balanced
RPRXRPRX on the overall AIQ Score, which weights Quality and Value at 30% each.
Growth
ABBVABBV on combined revenue and EPS growth.
Value
RPRXRPRX on the peer-relative Value factor, by 15 points.
Momentum
RPRXRPRX on the Momentum factor, by 14 points.
Lower downside
RPRXRPRX on Risk Resilience, by 9 points.
Analyst upside
ABBVABBV on implied upside to the consensus price target.
AIQ vs Wall Street
The model and the Street disagree here: AIQ favors RPRX, analyst targets favor ABBV. That disagreement is the most useful thing on this page.
| Measure | ABBV | RPRX | Note |
|---|---|---|---|
| Implied upside to target | +9% | -1.9% | ABBV has more room |
| Target dispersion | +24.3% | +14.3% | Lower is tighter analyst agreement |
| Consensus | Buy | Buy | Context, not a primary driver |
| Analysts covering | 13 | 3 | Higher coverage generally improves confidence |
The two are measuring different things. The AIQ Score reads current fundamentals, valuation, trend and risk; analyst targets price forward expectations. A divergence of this kind is either a contrarian opportunity or a sign the model is missing something already priced in — it is worth resolving before acting on either.
Analyst targets are expectations, not predictions. Dispersion matters as much as the midpoint.
AIQ Agreement Matrix
5 of 6 covered evidence groups favor RPRX. A wide gap backed by one group is a weaker case than a narrow gap backed by five.
| Evidence group | Favors | Reading |
|---|---|---|
| AIQ Score | RPRX | 52 vs 59 |
| Fundamentals | RPRXon balance | revenue growth 13.3% vs 6.9%; EPS growth 4.2% vs -94.1%; TTM ROE -136.5% vs 12.3%; gross margin 71.5% vs 89.4%; operating margin 29.3% vs 62.3% — RPRX takes 3 of 5 decided legs, not all of them |
| Valuation | RPRX | Value 36 vs 51 |
| Technicals | RPRX | Price vs 50-day 0.8% vs 8.5%; vs 200-day 12.3% vs 29.9% |
| Risk Resilience | RPRX | Risk Resilience 44 vs 53 |
| Analyst expectations | ABBV | Target upside 9% vs -1.9% |
✓ agrees with the overall verdict · ✕ points the other way. Groups marked “not covered” lack data on one or both of ABBV and RPRX and are excluded from the count.
AIQ Decision Stability
The two are close enough that your objective, not the score, should decide.
- The AIQ gap is moderate at 7 points.
- 5 of 6 covered evidence groups point the same way. (supports the conclusion holding)
- The lead has been steady session to session. (supports the conclusion holding)
- The leader is throwing conflicting signals. (argues the conclusion is provisional)
Stability combines the score gap, how broadly the evidence agrees, how steady the lead has been across daily snapshots, the current signal state on both names, and analyst dispersion on RPRX.
How the comparison changed
120 daily snapshots · Apr 24 – Sep 5RPRX lead: Stable — the AIQ differential has held near 7 points over 30 sessions.
- Today
- RPRX +7
- 52 vs 59
- 7 sessions ago
- RPRX +7
- 52 vs 59
- 30 sessions ago
- RPRX +7
- 48 vs 55
- 90 sessions ago
- RPRX +2
- 55 vs 57
The lead changed hands 3 times in this window, most recently on Jun 24 when ABBV moved ahead of RPRX.
AIQ Signal Divergence
Only the signals that bear on the head-to-head. A conflicted name is carrying bullish and bearish rules at the same time — the technical evidence is not pointing one way.
3 bullish / 1 bearish, conflicted
- Golden Cross Active — bullish, trend, long horizon (11.45%)
- EMA Ribbon Expansion Bullish — bullish, trend, medium horizon
- Uptrend Structure Active — bullish, trend, long horizon
6 bullish / 1 bearish / 1 neutral, conflicted
- Golden Cross Active — bullish, trend, long horizon (19.72%)
- Bollinger Band Squeeze — neutral, volatility, short horizon
- Keltner Channel Breakout — bullish, volatility, short horizon
RPRX leads the comparison while carrying a conflicted signal state, which is one reason the stability rating is not higher.
Price vs model alignment
Whether the latest session's price move confirms what the model did over the same session, or contradicts it.
Neither the price nor the AIQ Score moved enough in the latest session to confirm or contradict the other (price -1.44%, AIQ 0 points).
Neither the price nor the AIQ Score moved enough in the latest session to confirm or contradict the other (price +0.13%, AIQ 0 points).
What would flip this result
A state, not a forecast. These are the specific, observable changes that would reverse the verdict — not a price prediction.
- 1ABBV closes the Value gap — currently 15 points behind, the largest single contributor to RPRX's edge.
- 2ABBV generates a confirmed bullish trend signal it does not currently carry, such as MACD Bullish Crossover.
- 3RPRX's conflicting signal state resolves bearish — it currently carries 6 bullish and 1 bearish rules at once.
- 4A regime shift changes factor weighting — the composite weights Quality and Value at 30% each, so a rotation toward either would move the result most.
The full evidence
Every number behind the verdict. The leader is called above each group so you are not left to solve it from the table.
Fundamentals
RPRX leads on balance| Metric | ABBV | RPRX |
|---|---|---|
| Revenue growth (YoY) | 13.3% | 6.9% |
| EPS growth (YoY) | 4.2% | -94.1% |
| Gross margin | 71.5% | 89.4% |
| Operating margin | 29.3% | 62.3% |
| Return on equity (TTM) | -136.5% | 12.3% |
| Debt to equity | -11.93 | 1.31 |
Performance
RPRX leads 6 of 6 windows| Metric | ABBV | RPRX |
|---|---|---|
| 1 week (5 sessions) | 0.4% | 5.1% |
| 1 month (20 sessions) | 4.2% | 12.7% |
| 3 months (63 sessions) | 12.9% | 14.5% |
| 6 months (126 sessions) | 11.5% | 40.9% |
| Year to date | 12.2% | 61.2% |
| 1 year (252 sessions) | 21.1% | 74.5% |
Technicals
RPRX has the stronger structure| Metric | ABBV | RPRX |
|---|---|---|
| RSI (14) | 56.6 | 73.8 |
| ADX (14) | 21.7 | 34.8 |
| Price vs 50-day | 0.8% | 8.5% |
| Price vs 200-day | 12.3% | 29.9% |
| Volatility (1M, annualized) | 21.7% | 21.3% |
Risk
RPRX is the more resilient| Metric | ABBV | RPRX |
|---|---|---|
| Beta | -0.09 | 0.22 |
| Sharpe ratio | 0.69 | 2.35 |
| Sortino ratio | 1.15 | 3.85 |
| Max drawdown | -19.2% | -6.6% |
| Current drawdown | -3.6% | 0% |
| Annualized volatility | 26.6% | 23% |
| Value at risk (95%) | -2.4% | -2% |
Straight answers
Each answer is regenerated from the current snapshot, not written once and left to age.
Which is better, ABBV or RPRX?
On the Algovestiq AIQ Score, RPRX is the stronger of the two as of Sep 6, 2026, scoring 59 against ABBV's 52. The edge comes from value and momentum. ABBV is not without a case — it holds the better quality profile, which matters more if that is the objective you are optimizing for. This is a systematic score, not a recommendation: it ranks the two on the same evidence, it does not know your holding period or tax position.
Is ABBV or RPRX the better buy right now?
RPRX carries the stronger systematic profile as of Sep 6, 2026, and the comparison is rated Competitive — 5 of 6 covered evidence groups agree. A Competitive rating means the two are close enough that your objective, not the score, should decide.
Why does the AIQ Score favor RPRX over ABBV?
The composite weights Quality at 30%, Value at 30%, Momentum at 25% and Risk Resilience at 15%. RPRX leads Value by 15 points; RPRX leads Momentum by 14 points; RPRX leads Risk Resilience by 9 points. Where the two split, the factor with the larger weight carries the result.
Which has more analyst upside, ABBV or RPRX?
Analyst price targets imply +9% upside for ABBV and -1.9% for RPRX, so the Street currently favors ABBV. That points the opposite way to the AIQ Score, which favors RPRX. The two are measuring different things: the model reads current fundamentals, valuation, trend and risk; the Street is pricing forward expectations. A divergence of this kind is either a contrarian opportunity or a sign the model is missing something the analysts have already priced — it is the single most useful row on this page to investigate. Analyst targets are expectations, not predictions, and dispersion matters as much as the midpoint.
Which is better value, ABBV or RPRX?
RPRX is the better-valued of the two on the peer-relative Value factor. RPRX on the peer-relative Value factor, by 15 points. The Value factor reads valuation relative to sector peers and to the company's own fundamental quality, so it is not the same as simply having the lower multiple.
Which has stronger growth, ABBV or RPRX?
ABBV on combined revenue and EPS growth. Growth here is measured on reported revenue and earnings, not on forward estimates — it describes what the businesses have delivered, not what the Street expects next.
Which has stronger momentum, ABBV or RPRX?
RPRX on the Momentum factor, by 14 points. Momentum carries 25% of the AIQ composite. It has documented persistence over three- to twelve-month horizons, which makes it a timing input rather than a reason to hold something indefinitely.
Which is riskier, ABBV or RPRX?
RPRX is the more resilient of the two, so the other name carries the higher downside risk. RPRX on Risk Resilience, by 9 points. The Risk Resilience factor weights 15% of the composite; position sizing usually responds to it more usefully than the buy/avoid decision does.
Is ABBV more profitable than RPRX?
RPRX leads on the comparable margin measures — gross margin 71.5% vs 89.4%; operating margin 29.3% vs 62.3%; ttm roe -136.5% vs 12.3%.
Is RPRX's lead over ABBV getting stronger or weaker?
RPRX lead: Stable — the AIQ differential has held near 7 points over 30 sessions. This is measured from 120 daily comparison snapshots between 2026-04-24 and 2026-09-05. The lead has changed hands 3 times in that window, most recently on 2026-06-24, when ABBV moved ahead of RPRX.
What would change the ABBV vs RPRX verdict?
The result is a state, not a forecast, so it changes when the underlying evidence changes. Concretely: ABBV closes the Value gap — currently 15 points behind, the largest single contributor to RPRX's edge; ABBV generates a confirmed bullish trend signal it does not currently carry, such as MACD Bullish Crossover; RPRX's conflicting signal state resolves bearish — it currently carries 6 bullish and 1 bearish rules at once; a regime shift changes factor weighting — the composite weights Quality and Value at 30% each, so a rotation toward either would move the result most.
What do the current signals say about ABBV and RPRX?
ABBV: 3 bullish / 1 bearish, conflicted. RPRX: 6 bullish / 1 bearish / 1 neutral, conflicted. A conflicted state means bullish and bearish rules are active on the same name at once — the technical evidence is not pointing one way, and a decision taken on it carries more timing risk. The most decision-relevant rule on ABBV is Golden Cross Active (bullish, long horizon). On RPRX it is Golden Cross Active (bullish, long horizon).
Compare ABBV and RPRX with others
How this comparison is scored
The Algovestiq AIQ Score composites four factors — Quality (30%), Value (30%), Momentum (25%) and Risk (15%). Sentiment is reported separately as SentimentPulse and is not folded into the composite. Scores refresh every trading day, and this page regenerates from the latest snapshot rather than being written once.
The verdict names a leader, states how broadly six independent evidence groups agree, and rates how durable that conclusion is given the score gap, its recent trajectory and the current signal state on both names.
How to use side-by-side comparison →This comparison is informational and educational, not investment advice. AIQ scores update daily; re-check after earnings, guidance or macro data that materially changes either name’s factor profile.